Please use this identifier to cite or link to this item:
Title: Unique SERM-like properties of the novel fluorescent tamoxifen derivative FLTX1
Authors: Marrero-Alonso, Jorge
Morales, Araceli
García Marrero, Benito
Boto, Alicia
Marín, Raquel
Cury, Débora
Gómez, Tomás
Fernández-Pérez, Leandro 
Lahoz, Fernando
Díaz, Mario 
Keywords: Estrogen-Receptor Modulators
Drug-Dye Complex
Antiestrogen Tamoxifen
Molecular-Mechanisms, et al
Issue Date: 2013
Publisher: 0939-6411
Journal: European Journal of Pharmaceutics and Biopharmaceutics 
Abstract: Tamoxifen is a selective estrogen receptor modulator extensively used on estrogen receptor-positive breast cancer treatment. However, clinical evidences demonstrate the increased incidence of undesirable side effects during chronic therapies, the most life threatening being uterine cancers. Some of these effects are related to tissue-dependent estrogenic actions of tamoxifen, but the exact mechanisms remain poorly understood. We have designed and synthesized a novel fluorescent tamoxifen derivative, FLTX1, and characterized its biological and pharmacological activities. Using confocal microscopy, we demonstrate that FLTX1 colocalizes with estrogen receptor alpha (ER alpha). Competition studies showed that FLTX1 binding was totally displaced by unlabeled tamoxifen and partially by estradiol, indicating the existence of non-ER-related triphenylethylene-binding sites. Ligand binding assays showed that FLTX1 exhibits similar affinity for ER than tamoxifen. FLTX1 exhibited antiestrogenic activity comparable to tamoxifen in MCF7 and T47D cells transfected with 3xERE-luciferase reporter. Interestingly, FLTX1 lacked the strong agonistic effect of tamoxifen on ER alpha-dependent transcriptional activity. Additionally, in vivo assays in mice revealed that unlike tamoxifen, FLTX1 was devoid of estrogenic uterotrophic effects, lacked of hyperplasic and hypertrophic effects, and failed to alter basal proliferating cell nuclear antigen immunoreactivity. In the rat uterine model of estrogenicity/antiestrogenicity, FLTX1 displayed antagonistic activity comparable to tamoxifen at lower doses, and only estrogenic uterotrophy at the highest dose. We conclude that the fluorescent derivative FLTX1 is not only a suitable probe for studies on the molecular pharmacology of tamoxifen, but also a potential therapeutic substitute to tamoxifen, endowed with potent antiestrogenic properties but devoid of uterine estrogenicity. (C) 2013 Elsevier B.V. All rights reserved.
ISSN: 0939-6411
DOI: 10.1016/j.ejpb.2013.04.024
Source: European Journal of Pharmaceutics and Biopharmaceutics[ISSN 0939-6411],v. 85, p. 898-910
Appears in Collections:Artículos
Show full item record


checked on Apr 18, 2021


checked on Apr 18, 2021

Page view(s)

checked on Apr 18, 2021

Google ScholarTM




Export metadata

Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.